Answers are grounded in this paper and cite their sources.
Fanconi anemia (FA) is a rare genetic disease characterized by congenital abnormalities, progressive bone marrow failure and marked cancer predisposition. However, two recently identified FA complementation groups, FA-D1 and FA-N, are characterized by pronounced susceptibility to pediatric solid tumors. While FA has traditionally been viewed as an exclusive pediatric disorder, the clinical manifestations of FA may often only become apparent in young adults. Biallelic mutations in any one of 13 different genes leads to FA, and the products of the 13 FA genes are thought to act cooperatively in a cellular pathway, the FA pathway, to repair damaged DNA. Despite exciting recent breakthroughs in FA gene identification, the mechanism(s) of DNA repair regulated by this pathway remains poorly understood. Here, we will review our current understanding of the clinical and molecular features of FA, and discuss the implications of the FA pathway for cancer in the general population.
No takes yet. Share an insight, caveat, or question.
Harney et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: